Aims of this study: From cross-sectional and longitudinal population based studies as well as from autopsy studies it is well documented that total prostate volume increases with advancing age. However, it is not well known (1) which factors are ultimately responsible for this growth phenomenon; or (2) at what time in a persons life the growth tends to occur. At present at least a permissive role for testicular androgens is assumed to be involved in growth regulation. Other factors such as growth factors, epithelial-mesenchymal interaction, and the role of intact neural pathways are still poorly understood. We aimed to study a group of men with spinal cord injuries to determine whether the pattern of prostate enlargement would be different in men with partially or completely interrupted innervation of the pelvis and the prostate gland.
Introduction
Several cross-sectional and longitudinal population-based studies as well as autopsy series have shown that the size of the prostate gland increases with advancing age. 1±3 The factors that initiate and stimulate the growth of the prostate gland are not well understood. A critical level of androgens is necessary for the prostate to grow and develop. This demonstrates that male steroids have at least an important permissive role in prostate development. Their role in stimulating prostate growth and the development of benign prostatic hyperplasia (BPH) is less clear, and other factors are likely to contribute as well. 4 The prostate stroma probably plays a major role in prostate development and growth, 5 this effect occurs through mesenchymal-epithelial interactions, and is presumably mediated by growth factors that are synthesized in the stroma and are capable of controlling epithelial morphogenesis and glandular proliferation. The synthesis of some of these growth factors like Keratinocyte Growth Factor (KGF) appears to be under androgenic control, 6, 7 but it is possible that other signals including adrenergic stimulation are involved. 8 The prostate stroma is composed of smooth muscle cells, ®broblasts, and extracellular matrix (ECM), and has a rich nerve supply that consists of adrenergic, cholinergic and peptidergic ®bers. 9±11 There is experimental evidence to support a role for the autonomic nervous system in modulating prostate growth. It has been shown that in the rat, pelvic plexus denervation causes signi®cant morphologic and functional changes in the glandular epithelium. 12 In addition, in a similar model, surgical sympathectomy caused a decrease in ventral prostate weight, DNA, and protein content. 13 Furthermore, it has been shown that when grafted under the renal capsule, rat ventral prostate fails to synthesize and secrete prostate binding protein (PBP).
14 Under these conditions the prostate tissue is still exposed to the same hormonal milieu and stromal-epithelial interactions, but is devoided of its nerve supply. In fact, the decline in PBP synthesis is preceded by a decrease in the tissue content of catecholamines. Together, this evidence points to a possible role for the autonomic nervous system in maintaining the normal prostate architecture and function.
In this study we examine the prostate size in an age strati®ed cohort of patients with spinal cord injuries (SCI) of various levels and duration to determine whether intact neural pathways may play a role in regulating the growth of the prostate.
Material and methods
All patients enrolled in the Spinal Cord Injury Service at the Veterans Affairs North Texas Health Care System (VA NTHCS) were invited to take part in this study. Of those who responded, 43 agreed to participate and they form the basis of this report. All the participants understood the investigational nature of the study and signed the appropriate IRB (Institutional Review Board) approved consent forms. Each patient ®lled out a standardized questionnaire, and underwent physical and neurological examination. Testicular volume was assessed by standard orchidometer method. Blood samples were sent for serum prostate speci®c antigen (PSA), total and free serum testosterone (T), serum dihydrotestosterone (DHT), luteinizing hormone (LH) and follicle stimulating hormone (FSH). Total prostate (TPV) and transition zone (TZV) volumes were determined by transrectal ultrasound (TRUS) using a 6.5 end®re probe (Dornier Performa TM , Dornier Medtech, Marietta, Georgia). Anterior-posterior diameter or height (H) and transverse diameter (T) were measured in the largest transverse image. The longitudinal (L) diameter was measured in a mid sagittal plane using the maximal distance between the bladder neck and the apex of the prostate. The same measurements were applied to the transition zone. The ellipsoid volume formula (Prostate Volume p/66 H6T6L) was used to determine the volume of the entire gland and the transition zone. Peripheral zone volume (PZV) was determined by subtracting the transition zone volume from the total volume of the gland.
In addition, patients were invited to permit TRUS guided systematic biopsies of the prostate. These tissue samples were either frozen in OCT or paraf®ne embedded. Representative tissue sections were stained with hematoxylin and eosin, and Mason-Trichrome for histological analysis.
Patients were strati®ed by decade of life, and any possible differences between the various age groups were examined by one-way ANOVA test using the means, or in some cases the ranks when the corresponding groups were not normally distributed. Correlations were performed by the Pearson Product Moment Correlation method (SigmaPlot and SigmaStat, Jandel Scienti®c Software). A P-value of`0.05 was accepted as signi®-cant. Prostate volumes in this cohort of men with SCI were compared to those of men participating in the Olmsted County Study 15 and to a group of neurologically intact men who took part in another study conducted at the VA NTHCS assessing the correlation between prostate size measured by ultrasound and digital rectal exam (referred to as the Clinic Cohort). 3 
Results
A total of 43 men (33 Caucasian and 10 African American) were enrolled in this study. The mean age of all participants was 51 AE 9.8 s.d. (standard deviation) y with a range from 27 ± 73 y of age. For groupwise comparisons the 27 y old patient was combined with the 30 ± 39 y old and the 73 y old patient with the 60 ± 69 y old patients (Tables 1  and 2 ). Data were collected regarding the level injury. Eighteen (42.9%) patients had a cervical level injury, 17 (40.5%) a thoracic level injury, and 7 (16.7%) a lumbar level injury (level of injury was unknown in two patients). Because of the small size of patients we were unable to stratify both by age and by level of injury. The distribution of patients by injury level was similar in all age groups. As expected the mean time since injury differed when patients were strati®ed by decade of life with the younger patients having a shorter interval since injury (from 8.8 ± 22.2 y since injury for patients 30 ± 39 to 60 ± 69 y of age). However, these differences proved not to be signi®cant by ANOVA ( Table 1) .
As an indirect measure of an intact pituitary-gonadal axis we measured testicular volume with a standard orchidometer. Testicular volume was within normal ranges for all patients, and no differences were found when patients were strati®ed by decade of life (Table 1) .
Total prostate (TPV) and transition zone volume (TZV) were measured in all patients by TRUS with the Dornier Performa TM using the built-in ellipsoid volume formula. A correlation between age and TPV was performed and found to be not signi®cant (r 2 0.028, P 0.28) (Figure 1 ). When strati®ed by decade of life, the mean TPV increased from 22.4 ± 25.2 ml from men in their 30s to men in their 60s (not signi®cant by ANOVA) ( Table 1 ). The correlation between age and TZV was positive, signi®cant (r 2 0.158, P`0.05), while the correlation between age and peripheral zone volume (TPV-TZV] was negative and not signi®cant (r 2 0.012) (Figure 2 ). The mean TZV increased from 5.6 ± 10.7 for men in their 30s to men in their 60s (not signi®cant by ANOVA). We compared the prostate volume as strati®ed by decades of life with two other datasets, the Olmsted County Study (OC) data on community dwelling men without a clinical diagnosis of BPH or prostate disorder, and a clinic cohort (CC) of men in screening for BPH treatment studies (Figure 3) . Both datasets encompass patients from 40 to over 70 y of age, and thus no comparison can be made for the 30 ± 39 y old men with SCI. Total prostate volume was nearly identical in men in their 40s (22.2 vs 23.4 vs 22.2 for CC vs OC vs SCI). For men in their 50s and 60s the mean prostate volume in the OC and CC increased substantially, while there was no such increase in the SCI patients. The mean volumes for men in their 50s, 60s and 70s for the CC and OC were 29.1 vs 29.0 ml, 41.5 vs 34.6 ml, and 43.2 vs 39.1 ml, respectively. When testing pairwise for equal slopes, the difference between the CC and SCI was signi®cant (P 0.26), the difference between OC and SCI approached signi®cance (P 0.875), but the difference Figure 1 Correlation betwqeen age and total prostate volume (ml) determined by TRUS in 43 patients with SCI.
Prostate size, PSA and endocrine pro®le after spinal cord injury EA Benaim et al between OC and CC was not signi®cant (P 0.189) ( Figure 3 ). Although the TZV increased from a mean of 5.6 ± 10.7 ml in SCI men, the TZV in the CC increased from 7.2 ± 19.0 ml in men from their 40s to their 60s (Figure 4) , thus resulting in a twice as high mean TZV in men in their 60s, the group of men presumably most susceptible to the development of BPH in the transition zone. TZV was not measured in the community dwelling men in the OC study. Serum PSA was measured by the monoclonal method in all patients in an infection free interval without prior prostate manipulation (Hybritech). There was a modest correlation between age and serum PSA (r 2 0.19, P`0.05), and between TPV and serum PSA (r 2 0.26, P 0.002). The strongest correlation was found between TZV and serum PSA (r 2 0.46, P`0.001). The mean serum PSA increased from 1.0 AE 0.8 s.d. (range 0.1 ± 2.2) ng/ml for men in their 30s to 2.0 AE 1.4 s.d. (range 0.7 ± 4.6) ng/ml for men in their 60s (not signi®cant by ANOVA) ( Table 2) .
With very few exceptions, all values for serum testosterone, DHT, FSH and LH were within normal values (Table 2) . When strati®ed by decades of life, no differences could be detected for either one of the hormonal values by ANOVA with the exception of a signi®cant increase in serum FSH from 2.7 AE 1.4 (range 1.0 ± 4.7) mlU/ml for men in their 30s to 8.7 AE 5.2 (range 3.5 ± 6.0) mlU/ml for men in their 60s (P 0.02 by ANOVA) ( Figure 5 ).
Discussion
The data presented in this report suggest that patients with SCI do not show the expected age related increase in prostate volume that has been described in aging, neurologically intact men. There have been several studies reporting that patients with SCI may suffer from various endocrinological abnormalities affecting the pituitary ± gonadal axis. 16±20 The data presented in these reports are somewhat con¯icting and no common pattern can be identi®ed. Because of the potential implications that an Shown are the median (thin line), the 75% con®dence interval (box), the 95% Cl (whisker), outliers, and the mean (thick line). The differences between the groups were signi®cant (P 0.02) by ANOVA. altered pituitary ± gonadal axis could have on the growth and function of the prostate we measured concentrations of free and total testosterone, DHT, LH and FSH. We found normal levels for T and free T as well as for DHT for the entire group and for patients strati®ed by decades of life. In fact, we did not notice a decrease in serum T with advancing age as had been reported before. The mean LH levels for each age group fell within the normal adult male range and did not change signi®cantly with age. These data would argue against any hormonal disorders being responsible for the altered pattern of prostate growth observed in these patients. FSH level increased signi®cantly (P 0.02 by ANOVA) with advancing age. This has also been reported in aging males without neuropathic dysfunction, 21 and is probably related to a normal age related decline in sperm production.
Histologically there was no difference between tissue samples obtained from these patients with SCI and normal' controls. Gross histologic examination using H&E and Trichome staining revealed mostly a normal prostate anatomy. In some cases, there were scattered focal areas of gland atrophy and in¯ammation, but this was neither a prominent nor very prevalent feature, and occurred at a similar rate one would expect to see in the general population.
Serum PSA increased with age in a manner described previously in men without known prostatic diseases, 22 and only a few patients exceeded the age speci®c reference ranges.
The fact that the size of the prostate in patients with SCI did not increase at the same rate as seen in neurologically intact men despite a grossly normal tissue architecture, normal hormonal milieu, and normal serum PSA increase with age, provides some evidence that some of the stimuli that promote prostate growth in men without SCI, are absent or altered in men who suffered from a SCI. While other variables may account for the observed differences, we propose that intact neural pathways may be important in modulating human prostate growth.
There is experimental evidence that supports a role for the autonomic nervous system in regulating prostate growth. In his experiments on tissue recombinants utilizing rat ventral prostate and urogenital mesenchyme Thomson et al 14 found not only that catecholamines were necessary for the normal expression of PBP, but also that catecholamines had a mitogenic effect on cultured prostate stromal cells and equally important that alpha receptor blockade induced epithelial apoptosis in an experimental BPH model. 23 Moreover, the sympathetic system appears to play a role in end organ maturation, 24 smooth muscle growth, 25 and can modulate the smooth muscle phenotype. 26 These effects could explain the ®ndings of decrease tissue content of protein and DNA after sympathectomy reported by McVary et al, 13 and would be consistent with a decrease in cell numbers rather than the development of atrophy. In addition, there is some evidence that the expression of some growth factors like Fibroblast Growth Factor may be in¯u-enced by the sympathetic system. 8 This in turn, could have an impact on prostate growth.
Some may argue that the urogenital organs in this cohort of men with SCI are not truly denervated but decentralized. Decentralization however is not inconsequential, and is best exempli®ed by the changes observed in the bladder after SCI and other types of neurogenic dysfunction of the bladder. While it is dif®cult to discern to which extent these changes are secondary to an abnormal innervation or functional obstruction, abnormalities in both sympathetic and parasympathetic innervation have been well characterized in experimental models and they occur after both true denervation and decentralization. 27, 28 In fact, after, parasympathetic decentralization of the cat's bladder there is degeneration of postganglionic cholinergic axons in the bladder via transsynaptic neural degeneration. More important, re-innervation is dramatically reduced if the preganglionic sympathetic input is simultaneously interrupted. 27, 28 This indicates that intact preganglionic, sympathetic pathways have a trophic in¯uence on cholinergic nerve regeneration, and can affect the ultimate pattern of gland reinnervation. The level of the injury and its corresponding neurologic de®cit are probably important variables for which we were not able to correct.
We recognize several limitations to our study. The relatively small number of patients did not allow us to stratify them by both injury level. However, it is well known that the anatomic level of the injury and the type of neurological de®cit very often do not correlate. We are currently classifying our patients according to physical exam ®ndings and urodynamic evaluation to evaluate any possible correlation. Another important variable could be the time elapsed since the injury. Our preliminary data indicate that the mean time since injury was not signi®cantly different between the different age groups. We currently do not know at what time point the growth of the prostate takes place. The best evidence suggests an average growth of the prostate by 0.6 g/y with men 40 ± 59 y of age having a slower rate (0.4 ml/y) than older men aged 60 ± 79 (1.2 ml/y). 29 In order to differentiate between the in¯uence of the hormonal milieu and intact neural pathways, it would be ideal to compare groups of patients who suffered from SCI prior to puberty and after puberty. However, at present we do not have enough patients in such subgroups to allow meaningful conclusions.
Conclusions
Our preliminary report supports the concept that prostate growth during adulthood depends on factors other than hormonal in¯uences alone and suggests that intact neural pathways may play a role in modulating prostate growth. This idea is based on experimental evidence, the composition and innervation of the prostate, and the role of the stroma in regulating prostate growth and development. Our ®ndings need con®rmation in larger series of men strati®ed not only by age by also by level of injury and time since injury to validate these preliminary results. Furthermore, in depths histological studies of tissue specimens might be helpful in identifying a different pattern of innervation in prostates of men with SCI.
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